In a recent development, Texas Clinical Laboratory, BestCare Laboratory Services LLC, and its founder, have agreed to pay $5.7 million to settle a 2018 False Claims Act (FCA) judgement.
Arising under the Department of Justice’s ability-to-pay policy, the judgement was imposed based on assertions of fraudulent claims to federal healthcare programs. This resolution seems poised to put an end to protracted litigation surrounding allegations of misconduct in the clinical lab sector.
BestCare Laboratory Services LLC, now defunct, was accused of submitting false claims to Medicaid, Medicare and TRICARE, the health care program for uniformed service members, retirees, and their families.
With this settlement, a total of $789,652 has already been collected from BestCare and its founder by the DOJ. This report noted that the magnitude of the settlement, also reflects upon the seriousness of the situation, and is indicative of the justice department’s ongoing commitment to address issues of fraud in the healthcare domain in a stringent manner.
The circumstances leading to this settlement serve as a potent reminder for clinical laboraties, across the spectrum, to ensure strict compliance with healthcare regulations and avoid penalties. Regardless of the size of the organization, the legalities pertaining to healthcare claims and the penalties for violations are substantial.
Given the healthcare industry’s proliferating regulatory requirements, it is critical that companies adapt their operations to ensure alignment with the law, keeping daily operations under constant quality control and legal scrutiny.
This case stands as an exemplar of the importance of organizations timely addressing compliance issues, thereby saving significant costs in terms of potential litigations and financial penalties. For BestCare Laboratory and its founder, the substantial financial impact of the False Claims Act violation substantiates the relevance and imperative nature of regulatory compliance in the healthcare sector.